IB Biology HL D3.3 Homeostasis Questions
Practise IB Biology HL D3.3 by explaining feedback control, blood glucose, thermoregulation, ultrafiltration and ADH responses.
- Syllabus
- First assessment 2025
- Course
- Biology HL
- Level
- HL
Practise IB Biology HL D3.3 by explaining feedback control, blood glucose, thermoregulation, ultrafiltration and ADH responses.
The dimensions of four structures were measured in the hearts of eleven patients with anorexia and in the same number of control subjects.
(a) Discuss the support provided by the data for the claim that anorexia leads to the breakdown of heart tissue.
(b) In control subjects, blood potassium levels are maintained, through homeostasis, between 3.5 and 4.5 mmol litre −1. In patients with anorexia, blood potassium can fall below this level. This is known as hypokalemia. In patients with kidney failure, levels can rise above this range, causing hyperkalemia. The traces show the electrocardiograms (ECGs) of a patient with hypokalemia, a normal subject and a patient with hyperkalemia.
Sometimes hyperkalemia occurs as a body tries to respond to low blood pH . State the normal range of blood pH in the human body.
around 7.4 or 7.35 to 7.45
Living organisms have mechanisms for preventing or reducing change.
Describe the mechanisms used to keep blood glucose levels within narrow limits in humans.
a. pancreas cells monitor blood glucose concentrations;
b. glucagon secreted by alpha cells and insulin be beta cells;
c. glucagon/insulin/hormones secreted into/transported by bloodstream;
d. insulin secreted when glucose concentration rises/is high;
e. insulin stimulates uptake of glucose by liver/muscle/body cells;
f. insulin stimulates conversion of glucose to glycogen (in liver/muscle cells);
g. insulin stimulates body cells to use glucose instead of fat in cell respiration;
h. glucagon secreted when glucose concentration falls/is low;
i. glucagon stimulates breakdown of glycogen to glucose (by liver/muscle cells);
j. negative feedback (is used to regulate blood glucose concentration);
7
Marking guidance:
max
Type I diabetes is a leading cause of death in advanced countries and is associated with various severe or fatal complications, including blindness, kidney failure, heart disease, stroke, neuropathy, and amputations. Embryonic stem cells are considered to be a powerful tool in the treatment of diabetes.
In a study, embryonic stem cells were grown in culture and tested for insulin mRNA. A drug was injected into two groups of healthy mice in order to simulate type I diabetes 15 days prior to the transplant of embryonic stem cells. The mice in the transplant group received embryonic stem cells that produce insulin mRNA. The control group did not receive the transplant. The graph shows the blood glucose concentration in both groups.
Outline the cause of type I diabetes in humans.
a. «autoimmune» destruction of beta/β cells
b. reduced/insufficient/no production of insulin
Compare and contrast the concentration of blood glucose resulting from the embryonic stem cell transplant with the control.
a. decrease in transplant group «after treatment» in contrast to control group which does not decrease/decreases only very slightly «initially»/increases/is higher than treatment group
b. glucose «remains» lower in transplant group «than control group» for 2 weeks/ 3 weeks/for a time
c. «in the 4th week» transplant group rises back to level before transplant/to higher level than before transplant/to «near» level of control group
Evaluate the effectiveness of the embryonic stem cell treatment in controlling blood glucose.
In a second study, a group of patients recently diagnosed with type I diabetes received a transplant of stem cells. Based on their need for insulin after the transplant, participants were divided into two groups. Their C-peptide production levels were measured for 24 months as the levels indicate the degree of pancreatic beta-cell function. Group 1 did not require insulin and group 2 required insulin occasionally during the study. The graphs show the levels of C-peptides in each individual of both groups 1 and 2.
Graphs removed for copyright reasons
a. glucose level still higher than normal/higher than 100 «mg»/higher than it was before the drug injection
b. effective/lowers blood glucose for 3 weeks/temporarily/for a short time
OR
glucose level rises back in 4th week/by day 28
OR
rises back to level of control group
OR
rises again but not above control group